Noticias y Actividades de Catalyst Pharmaceuticals

Catalyst Pharmaceuticals es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Catalyst Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización CPRX (US).

Ver el organigrama con sus 17 ejecutivos principales

Biografías más buscadas en Catalyst Pharmaceuticals

• Richard Daly, Director and Chief Executive Officer
• Patrick McEnany, Non-Executive Chairman of the Board
• David Tierney, Director

Recientes movimientos de ejecutivos en Catalyst Pharmaceuticals

• Charles O'Keeffe, Lead Independent Director, abandonará la empresa en may.. de 2025  (noticia publicada el 28 de enero de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals tiene 1.833 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
• Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado el 12 de marzo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Paul Meister - Chairman of the Board en Amneal Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Catalyst Pharmaceuticals

• Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference : Catalyst Pharmaceutical
• Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update : Catalyst Pharmaceutical
• Press Releases : Catalyst Pharmaceutical
• Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals : Catalyst Pharmaceutical
• Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE® : Catalyst Pharmaceutical
• Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo : Catalyst Pharmaceutical
• Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023 : Catalyst Pharmaceutical
• Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference : Catalyst Pharmaceutical
• Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE® : Catalyst Pharmaceutical
• Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer : Catalyst Pharmaceutical
• View more press releases Close

Redes sociales sobre Catalyst Pharmaceuticals

• Catalyst Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Catalyst Pharmaceuticals en LinkedIn, Twitter y YouTube